

# Thomas G Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020086/publications.pdf>

Version: 2024-02-01

58  
papers

2,505  
citations

361413

20  
h-index

206112

48  
g-index

58  
all docs

58  
docs citations

58  
times ranked

4378  
citing authors

#	ARTICLE	IF	CITATIONS
1	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	16.8	847
2	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
3	A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. <i>Blood</i> , 2017, 129, 3294-3303.	1.4	155
4	Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. <i>Blood</i> , 2016, 127, 2561-2568.	1.4	139
5	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
6	Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. <i>Cells</i> , 2019, 8, 1522.	4.1	109
7	The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2375-2386.	4.1	90
8	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 41.	6.2	80
9	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology</i> , 2020, 16, 4347-4358.	2.4	60
10	Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. <i>British Journal of Haematology</i> , 1996, 95, 535-541.	2.5	56
11	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 131-139.e1.	0.4	54
12	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	12.8	38
13	Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 189-196.	2.0	38
14	The development of potential antibody-based therapies for myeloma. <i>Blood Reviews</i> , 2015, 29, 81-91.	5.7	33
15	Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1218-1224.	2.0	32
16	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. <i>Blood</i> , 2010, 116, 37-37.	1.4	31
17	Interferon-induced thrombocytopenia: Is it time for thrombopoietin?. <i>Hepatology</i> , 1998, 28, 1430-1432.	7.3	28
18	Multiple Myeloma: Current Advances and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 255-263.	0.4	27

#	ARTICLE	IF	CITATIONS
19	Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2008-2020.	4.1	25
20	DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. <i>Leukemia</i> , 2020, 34, 938-941.	7.2	24
21	Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1974-1982.	2.0	23
22	The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. <i>PLoS ONE</i> , 2020, 15, e0237155.	2.5	21
23	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	5.2	21
24	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	5.2	20
25	Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6028-6038.	7.0	20
26	Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 126.	17.0	19
27	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. <i>Haematologica</i> , 2022, 107, 1397-1409.	3.5	16
28	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5344-5348.	5.2	16
29	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. <i>Blood</i> , 2020, 136, 7-8.	1.4	15
30	Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 876-883.	2.0	13
31	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011, 118, 1876-1876.	1.4	13
32	Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2022, 3, 97-108.	1.0	13
33	Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 477.e1-477.e7.	1.2	12
34	Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1030-1036.	2.0	11
35	Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. <i>Leukemia and Lymphoma</i> , 2016, 57, 1560-1566.	1.3	11
36	Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2013, 122, 1750-1750.	1.4	11

#	ARTICLE	IF	CITATIONS
37	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1211-1219.	1.3	10
38	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. <i>Cancer</i> , 2021, 127, 1816-1826.	4.1	9
39	Inhibition of MET Signaling with Ficlatusumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. <i>Blood Cancer Discovery</i> , 2021, 2, 434-449.	5.0	7
40	Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1253-1257.	0.9	6
41	Serial comprehensive geriatric and quality of life assessments in adults age ≥50 years undergoing autologous hematopoietic cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 531-539.	1.0	6
42	A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials. <i>Blood</i> , 2012, 120, 2962-2962.	1.4	6
43	Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e961-e985.	0.4	4
44	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. <i>Frontiers in Oncology</i> , 2021, 11, 783703.	2.8	4
45	Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110469.	0.9	3
46	Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. <i>Clinical Transplantation</i> , 2021, , e14541.	1.6	3
47	A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 377-383.	0.4	2
48	Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 246-256.e2.	0.4	2
49	Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021, 17, 4849-4860.	2.4	2
50	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , 2011, 118, 1875-1875.	1.4	2
51	Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 309.e1-309.e9.	1.2	2
52	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. <i>International Journal of Hematology</i> , 2022, 116, 553-562.	1.6	2
53	Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1317-1317.	1.4	1
54	Prostate $\text{DCE-MRI}$ with correction using an approximated analytical approach. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2525-2537.	3.0	0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0237155.		0
56	Title is missing!. , 2020, 15, e0237155.		0
57	Title is missing!. , 2020, 15, e0237155.		0
58	Title is missing!. , 2020, 15, e0237155.		0